PUBLIC COMPANY
saveGLAXOSMITHKLINE
USupdated 2mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1A Study of GSK4771261 in Healthy Participants Aged 25 to 55 Years of Age Inclusive
- phase1First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy Adults
- phase3A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]
- phase2A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)
- phase1A Study to Evaluate Gepotidacin Exposure in Breast Milk of Healthy Lactating Women
- phase2A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD)
- phase2A Legacy Study in Participants With Gastrointestinal Stromal Tumors (GIST)
- phase3A Study to Investigate the Efficacy and Safety of GSK5784283 Compared With Placebo in Participants With Uncontrolled Asthma (PERSIST ASTHMA-2)
🐶 Hiring Signal
News
- No more Nordisk as Novo goes it alone amid rebranding pushAs Novo Nordisk continues its epic battle with Eli Lilly for market share in the increasingly competitive obesity and diabetes space, Novo is launching a major rebrand of its business, logo and name.fiercebiotech · 21d ago
- TwinStrand wins patent case; GSK’s hepatitis B drug approved in JapanTwinStrand Biosciences wins patent case: The DNA sequencing company, which spun out of the University of Washington, announced on Monday that it won a patent infringement lawsuit against a Californ…endpoints · 1mo ago
- FDA approves Nuvalent's cancer drug, a week after GSK closed $10.6B buyoutGSK's $10.6 billion acquisition of Nuvalent is delivering surprisingly early results. The FDA on Wednesday approved one of Nuvalent's lung cancer medicines two months earlier than projected, and th…endpoints · 2mo ago
- STAT+: Pharmalittle: We’re reading about rising drug shortages, GSK coughing up a trial loss, and moreThe number of active medication shortages in the U.S. rose to 227 in the second quarter of 2026stat · 2mo ago
- Beyond Boston: Unlikely cities stake biotech claimsAs Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.biopharma_dive · 3mo ago
- Ex-iTeos CEO starts fresh at GSK neuro partner; Genentech loses yet another key scientist→ Michel Detheux has succeeded Rita Balice-Gordon as CEO of Danish neuro biotech Muna Therapeutics, which is partnering with GSK on Alzheimer’s treatments. Balice-Gordon will slide over to ...endpoints · 3mo ago
- The hidden history of BPC-157, a favorite MAHA peptideA compound named “substance God help me” by its longtime champion could benefit from RFK Jr.'s favorable views on using peptides.stat · 4mo ago
comments(0)
5-min edit window · permanent after that